Only 19% use AI predictive models in cancer care despite strong belief in impact; 2026 Oncology Care Index highlights reimbursement, training, funding barriers.
|Slideshows|August 13, 2018
Top 10 Cancer Treatment Stats Health Execs Should Know
Author(s)Mark Rowh
If it's true that a picture is worth a thousand words, the same can be said for numbers. For any healthcare executive, a look at relevant statistics can be revealing. Here are some of the top stats to know.
Advertisement
If it's true that a picture is worth a thousand words, the same can be said for numbers. For any healthcare executive, a look at relevant statistics can be revealing. Here are some of the top stats to know.
Advertisement
Related to this article
AACR Cancer Progress Report 2026 highlights a 35% U.S. cancer death decline, new FDA advances, persistent disparities, and urgent calls for stronger NIH/NCI funding.
A meta-analysis of 13 trials and 969 patients saw some short-term reductions in cancer-related pain and anxiety, especially during procedures, when using virtual reality.
Chad Hatfield, Pharm.D., M.H.A., BCPS, vice president and chief pharmacy officer of UC Davis Health, says pharmacists are embedded in “nearly all specialties," with more than 150 holding board certification.
A new Spherix Global Insights survey shows providers want administrative support for prior authorization while patients prioritize access and affordability
8-year data show adjuvant Tagrisso boosts survival after surgery for EGFR-mutated NSCLC, reshaping early Lung Cancer care and adherence.
Sova, a clinical advisor for Employers Health, expects more employers to exclude GLP-1s for obesity but urges a look at coverage for specific cardiometabolic conditions.
Employers Health’s Alexis Sova says employers excluding GLP-1s now lean on weight management programs and direct-to-employer deals, not a hard cutoff.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Alexis Sova, Pharm.D., MBA, on where GLP-1 coverage goes next | PBMI 2026
2
Alexis Sova, Pharm.D., MBA, on GLP-1 access when coverage ends | PBMI 2026
3
Systemic inflammation present even in mild hidradenitis suppurativa
4
Large study finds GLP-1 drugs may lower fracture risk in Type 2 diabetes
5